Difference between revisions of "Toremifene (Fareston)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.<ref name="insert">[http://www.fareston.com/docs/GTX-Prescribing-Information.pdf Toremifene (Fareston) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/toremifene.pdf Toremifene (Fareston) package insert (locally hosted backup)]</ref><ref>[http://fareston.com/ Fareston manufacturer's website]</ref> | Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.<ref name="insert">[http://www.fareston.com/docs/GTX-Prescribing-Information.pdf Toremifene (Fareston) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/toremifene.pdf Toremifene (Fareston) package insert (locally hosted backup)]</ref><ref>[http://fareston.com/ Fareston manufacturer's website]</ref> | ||
| Line 17: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 5/29/1997: Initial FDA approval | * 5/29/1997: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Acapodene, Fareston | ||
==References== | ==References== | ||
| Line 22: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
| + | [[Category:Protein expression-specific medications]] | ||
| + | |||
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
Revision as of 16:46, 1 November 2017
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Toremifene (Fareston) patient drug information (Chemocare)[4]
- Toremifene (Fareston) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/29/1997: Initial FDA approval
Also known as
- Brand names: Acapodene, Fareston